Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6257573 | 0.93 | TSHR (0.38) | ALDH1A1TDP1JAK2JAK1TYK2 | |
| SCHEMBL6242389 | 0.85 | GNRHR (0.39) | ALDH1A1TDP1SMN1; SMN2HDAC1HDAC8 | |
| SCHEMBL7746317 | 0.82 | MEN1 (0.43) | ALDH1A1TDP1SMN1; SMN2AGTR1AGTR2 | |
| SCHEMBL6243389 | 0.80 | GNRHR (0.41) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6504017 | 0.78 | CYP3A4 (0.42) | CYP3A4SMN1; SMN2HDAC1HDAC8 | |
| SCHEMBL6274097 | 0.78 | CYP3A4 (0.58) | ALDH1A1CYP3A4SMN1; SMN2HDAC1HDAC8 | |
| SCHEMBL6219935 | 0.76 | MEN1 (0.42) | ALDH1A1TDP1HDAC1HDAC8 | |
| SCHEMBL6222254 | 0.76 | TP53 (0.38) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6489815 | 0.74 | MEN1 (0.38) | CYP3A4HDAC1HDAC8JAK2JAK1 | |
| SCHEMBL6493197 | 0.73 | TP53 (0.35) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919331-B2 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1461035-A4 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1461035-A2 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | Bristol-Myers Squibb Company (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-06 | — | — | US | disclosed |
| WO-2003053344-A2 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | ALDH1A1 3132/4885TDP1 3829/4885CYP3A4 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.